Document is current
Any future updates will be listed below
-
Authors
Sarkar, Sunit https://orcid.org/0000-0003-3857-1776
Tran, Ben
Horvath, Lisa https://orcid.org/0000-0001-6842-9223
Lam, Michael https://orcid.org/0000-0002-0807-3701
Savas, Peter https://orcid.org/0000-0001-5999-428X
Grimison, Peter https://orcid.org/0000-0002-2653-1657
Whittle, James R.
Kuo, James C. https://orcid.org/0000-0001-7123-8591
Signal, Nicole
Edmonds, David
Hogg, Philip https://orcid.org/0000-0001-6486-2863
Rischin, Danny
Desai, Jayesh https://orcid.org/0000-0003-4246-9344
Hamilton, Anne https://orcid.org/0000-0003-0368-9838
-
Funding
Funding for this research was provided by:
National Health and Medical Research Council (1002645, 1110219)
Cancer Council NSW (PG 11-03)
Australian Cancer Research Foundation
UNSW Foundation
- License Information
-
More Information
Article History
Received: 11 October 2020
Accepted: 28 December 2020
First Online: 26 January 2021
Compliance with ethical standards
:
: Ben Tran has received financial support from Amgen and Astellas Pharma. Ben Tran has received honoraria from Astellas Pharma, Janssen-Cilag, Sanofi, Tolmar and Amgen. Ben Tran has received institutional research funding from Astellas Pharma, Janssen-Cilag, Amgen, Pfizer, Genentech, AstraZeneca, Bayer, Bristol-Myers Squibb, Merck Sharp and Dohme and Ispen. Danny Rischin received grants from Merck, Bristol-Myers Squibb, Roche and Regeneron. Danny Rischin has also received grants and personal fees from GlaxoSmithKline and Merck Sharp and Dohme. Ben Tran has acted in an advisory or consultant role for Amgen, Astellas Pharma, Bayer, Sanofi, Tolmar, Janssen-Cilag, Bristol-Myers Squibb, Ipsen, Merck Sharp and Dohme and AstraZeneca. Peter Savvas has acted as an uncompensated Consultant for Roche-Genentech. Danny Rischin has had uncompensated role on Trial Steering Committees and/or advisory boards for Merck Sharp and Dohme, Bristol-Myers Squibb, GlaxoSmithKline, Regeneron and Sanofi.
